Chargement en cours...
非小细胞肺癌MET基因突变的机制及靶向药物研究进展
Mesenchymal-epithelial transition factor (MET) gene is an important tumor driver gene of non-small cell lung cancer (NSCLC). Drugs targeting MET 14 exon skipping mutation bring new hope to patients. MET inhibitors that are currently on the market or are about to be marketed include: crizotinib, cabo...
Enregistré dans:
| Publié dans: | Zhongguo Fei Ai Za Zhi |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
中国肺癌杂志编辑部
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7406436/ https://ncbi.nlm.nih.gov/pubmed/32702795 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.32 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|